Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q3 FY2018-19 Earnings Presentation
9 slides from Aurobindo Pharma's earnings presentation, Feb 7, 2019
Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
~ AUR BINDO February 7,2019 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI ·400 051 MUMBAI ·400 001 Company Code No. AUROPHA
Slide 2: Q3 FY18-19 Earnings Presentation
Q3 FY18-19 EARNINGS PRESENTATION 7th February 2019
Slide 3: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 4: Consolidated Financial & Business Highlights – Q3FY19
Consolidated Financial & Business Highlights – Q3FY19 Key Financial Highlights • Revenue from Operations increased by 21.5% YoY and 10.9% QoQ to INR 5,269.7 Cr, led by strong growth in both Formulations and APIs • EBIDTA before Forex and Other income at INR 1,086.4 Cr vs INR 1,025.6 Cr in Q3FY18 and
Slide 5: US Filings Snapshot
US Filings Snapshot Addressable Cumulative ANDA Filings and Approvals Therapy ANDAs Market Size (US$ Bn) Anti Diabetic 19 9.0 ARV** 42 6.0 CNS 91 24.5 Controlled Substances 17 1.4 CVS 81 24.2 Gastroenterological 30 3.7 Ophthalmics 11 0.4 Others 161 16.1 Penem 2 0.5 Respiratory (inc. Nasal) 12 0.7 On
Slide 6: Consolidated Financial Performance – Q3FY19 YoY
Consolidated Financial Performance – Q3FY19 YoY Q3 Q3 % Value INR Cr Revenue from Operations - Breakup FY19 FY18 Chg Value in INR Cr Q3FY19 Q3FY18 % Chg Formulations 4,347.8 3,570.2 21.8 USA 2,433.2 1,909.6 27.4 API 921.7 765.7 20.4 EU 1,292.8 1,171.6 10.3 Formulations % of sales 82.5% 82.3% Growth
Slide 7: Consolidated Financial Performance – Q3FY19 QoQ
Consolidated Financial Performance – Q3FY19 QoQ Q3 Q2 % Value INR Cr Revenue from Operations - Breakup FY19 FY19 Chg Value in INR Cr Q3FY19 Q2FY19 % Chg Formulations 4,347.8 3,934.8 10.5 USA 2,433.2 2,226.8 9.3 API 921.7 816.6 12.9 EU 1,292.8 1,156.5 11.8 Formulations % of sales 82.5% 82.8% Growth m
Slide 8: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-16 Mar-17 Mar-18 Sep-18 Dec-18 Closing Rate1 US$ = 66.25 64.85 65.17 72.485 69.775 INR Fx Loan restated in 4,956.7 3,121.5 4,766.9 5,493.4 5,381.8 748 481 731 758 771 INR Rupee Loan 46.9 244.8 4.1 282.2 289.7 Sales Tax Deferment 41.9 0.0 0.0 0.0 0.
Slide 9: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725000/5401 +91 98486 67906 Email: ir@aurobindo.com Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Register
Aurobindo Pharma — Q3 FY2018-19 Earnings Presentation on 6ix